Treos Bio

London, United Kingdom Founded: 2013 • Age: 13 yrs
Developer of cancer vaccines and companion diagnostics
Request Access

About Treos Bio

Treos Bio is a company based in London (United Kingdom) founded in 2013.. Treos Bio has raised $22 million across 2 funding rounds from investors including Luminous Ventures and Isabel Fox. The company has 12 employees as of December 31, 2020. Treos Bio offers products and services including PolyPEPI1018 and PEPI Technology. Treos Bio operates in a competitive market with competitors including Guardant Health, MedGenome, Foundation Medicine, ArcherDX and Natera, among others.

  • Headquarter London, United Kingdom
  • Employees 12 as on 31 Dec, 2020
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Treos Bio Limited
  • Date of Incorporation 20 Oct, 2016
  • Jurisdiction LONDON, ENGLAND
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
    $-7.06 M (USD)
    19
    as on Dec 31, 2018
  • EBITDA
    $-7.05 M (USD)
    19
    as on Dec 31, 2018
  • Total Equity Funding
    $22 M (USD)

    in 2 rounds

  • Latest Funding Round
    $14 M (USD), Series B

    Mar 31, 2021

  • Investors
  • Employee Count
    12

    as on Dec 31, 2020

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Treos Bio

Treos Bio offers a comprehensive portfolio of products and services, including PolyPEPI1018 and PEPI Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Vaccine for colorectal cancer inducing strong immune responses.

Platform for developing effective peptide-based cancer treatments.

People of Treos Bio
Headcount 1-10
Employee Profiles 8
Board Members and Advisors 12
Employee Profiles
People
Gábor Illés
CFO
People
Christopher C. Gallen
CEO
People
Hagop Youssoufian
Chair of Medical Strategy
People
John Hautman
Chief Legal Officer

Unlock access to complete

Board Members and Advisors
people
Isabel Fox
Director
people
Ruti Alon
Director
people
David Feigal
Clinical Advisor
people
Enikő R. Tőke
Director

Unlock access to complete

Funding Insights of Treos Bio

Treos Bio has successfully raised a total of $22M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $14 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $14.0M
  • First Round

    (13 Feb 2017)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2021 Amount Series B - Treos Bio Valuation Luminous Ventures
Feb, 2017 Amount Series A - Treos Bio Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Treos Bio

Treos Bio has secured backing from 2 investors, including venture fund and angel investors. Prominent investors backing the company include Luminous Ventures and Isabel Fox. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Angel
Investor Description Founded Year Domain Location
Early-stage startups are funded by Luminous Ventures venture capital firm.
Founded Year Domain Location

Isabel Fox

Angel investor focusing on Indian startups, with a background in tech and innovation.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Treos Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Treos Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Treos Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Treos Bio

Treos Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, MedGenome, Foundation Medicine, ArcherDX and Natera, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
DNA sequencing, bioinformatics, and multiomics services are provided.
domain founded_year HQ Location
Genomics-based diagnostic tests for cancer are provided.
domain founded_year HQ Location
Molecular cancer diagnostic products are developed using patented AMP technology.
domain founded_year HQ Location
Developer of cell-free DNA testing for oncology, women’s health, and organ health
domain founded_year HQ Location
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Treos Bio

When was Treos Bio founded?

Treos Bio was founded in 2013 and raised its 1st funding round 4 years after it was founded.

Where is Treos Bio located?

Treos Bio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Is Treos Bio a funded company?

Treos Bio is a funded company, having raised a total of $22M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8M, raised on Feb 13, 2017.

How many employees does Treos Bio have?

As of Dec 31, 2020, the latest employee count at Treos Bio is 12.

What does Treos Bio do?

Developer of cancer vaccines and companion diagnostics. Its platform technology uses proprietary algorithms to mine patient genetic profiles and match them to their response to therapeutic vaccines. It has two diagnostic products. The PEPI test is a genetic test that predicts the patients antigen-specific immune response, which in turn can be used to predict the patients response to therapeutic cancer vaccines. The PEPI test is approved as an IVD kit in Europe. The other diagnostic test under development is the Melanoma PEPI Test for identifying high-risk melanoma patients. In addition, the company is developing the PolyPEPI vaccine and companion diagnostic family of products for melanoma, breast cancer, and lung cancer. The companion diagnostics will be used for the biomarker-based stratification of patients.

Who are the top competitors of Treos Bio?

Treos Bio's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.

What products or services does Treos Bio offer?

Treos Bio offers PolyPEPI1018 and PEPI Technology.

Who are Treos Bio's investors?

Treos Bio has 2 investors. Key investors include Luminous Ventures, and Isabel Fox.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available